⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
globenewswire.com
IMRX
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com
IMRX
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
globenewswire.com
IMRX
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
globenewswire.com
IMRX
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
globenewswire.com
IMRX
Immuneering to Present at the ESMO Congress 2026
globenewswire.com
IMRX
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
globenewswire.com
IMRX